ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Towa Pharmaceutical Co., Ltd.

Business Summary

Towa Pharmaceutical Co., Ltd. engages in the manufacture and distribution of pharmaceutical products. Its products include neurological and anti-allergic drugs, cardiovascular and respiratory drugs, gastrointestinal drugs, antibiotics and chemotherapeutic drugs, vitamins; hormone drugs, and other metabolic drugs. The company was founded in June 1951 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue154,900M1,460.52M
Gross Profit65,452M617.13M
Operating income19,929M187.90M
Income before tax18,728M176.58M
Net income13,958M131.60M
EBITDA30,354M286.20M
Diluted EPS271.932.56
Dividends Per Share440.41
Total Assets245,668M2,223.23M
Total liabilities129,066M1,168.01M
Total equity116,599M1,055.19M
Operating cash flow12,008M113.22M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 84,949M 93,430M 105,104M 110,384M 154,900M
Gross Profit 39,047M 43,051M 48,399M 50,646M 65,452M
Operating income 7,143M 11,644M 16,283M 16,171M 19,929M
Income before tax 7,237M 9,833M 18,886M 20,709M 18,728M
Net income 5,576M 6,495M 13,475M 14,503M 13,958M
EBITDA 15,123M 19,817M 24,623M 24,456M 30,354M
Diluted EPS 104.74 122.02 253.31 272.61 271.93
Dividends Per Share 31.66 31.66 35.83 44 44
Total Assets 165,247M 177,655M 189,158M 230,016M 245,668M
Total liabilities 90,299M 97,733M 97,386M 125,349M 129,066M
Total equity 74,945M 79,920M 91,771M 104,665M 116,599M
Operating cash flow 10,195M 19,230M 19,002M 19,164M 12,008M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 784.47M 842.98M 947.78M 1,015.25M 1,460.52M
Gross Profit 360.58M 388.43M 436.44M 465.81M 617.13M
Operating income 65.96M 105.05M 146.83M 148.73M 187.90M
Income before tax 66.83M 88.71M 170.30M 190.47M 176.58M
Net income 51.49M 58.60M 121.51M 133.39M 131.60M
EBITDA 139.65M 178.80M 222.03M 224.93M 286.20M
Diluted EPS 0.96 1.10 2.28 2.50 2.56
Dividends Per Share 0.29 0.28 0.32 0.40 0.41
Total Assets 1,482.96M 1,670.47M 1,708.97M 2,130.66M 2,223.23M
Total liabilities 810.36M 918.97M 879.84M 1,161.12M 1,168.01M
Total equity 672.57M 751.48M 829.11M 969.52M 1,055.19M
Operating cash flow 94.14M 173.50M 171.35M 176.25M 113.22M

Valuation Measures

Mar 2021
PER8.61
ROA5.86%
ROE12.61%
Operating margin12.86%
Profit margin9.01%

Key executives

  • President & Representative Director: Itsuro Yoshida
  • Executive Officer & Deputy General Manager-Sales: Masaji Morikawa
  • Executive Officer & GM-Product Strategy: Takeshi Sugiura
  • Executive Officer & Manager-Accounting: Shinya Kida
  • Senior Executive Officer & GM-Administration: Kenichi Inoue

Shareholders

  • YOSHIDA FAMILY /TOWA PHARMACEUTICAL/ (39.0%)
  • Towa Pharmaceutical Co., Ltd. (4.4%)
  • YOSHIDA ITSURO (2.8%)
  • Towa Pharmaceutical Business Association (2.7%)
  • Brown Capital Management LLC (2.6%)
  • Towa Pharmaceutical Employee Stock Ownership Plan (1.7%)
  • Nomura Asset Management Co., Ltd. (1.7%)
  • The Vanguard Group, Inc. (1.3%)
  • Fidelity Investments Canada ULC (1.3%)
  • Yoshida Estate YK (1.2%)

Contact Details

Related Companies

  • Towa Pharmaceutical Europe SL
  • Towa Pharma International Holdings SL (Sociedad Unipersonal)
  • Greencaps Pharmaceutical Co., Ltd.
  • Towa Pharmaceutical Restricted Stock Compensation Plan
  • Pensa Investments SL
  • Daichi Kasei KK
  • J-Dolph Co., Ltd.
  • Towa Pharmaceutical Business Association
  • Towa Pharmaceutical Employee Stock Ownership Plan

Competitors

    Last Updated on 27 Jul, 2021

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Try 1 month for $0.99

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends July 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to Nikkei Asia has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more